The 16th Annual Advanced Pain Conference and Practical Workshop
29-31 August, 2011, Budapest, Hungary

www.congressline.hu/pain2011

Program Book and Syllabus
CONTENT

Greetings ................................................................. 4.
WIP Council .............................................................. 6.
Faculty ........................................................................ 7.
Acknowledgement ....................................................... 8.
Exhibitor & Sponsor Profiles ........................................ 9.
General Information .................................................. 11.

Detailed program

29 August ................................................................... 14.
30 August ................................................................... 15.
31 August ................................................................... 16.
Awards Ceremony ......................................................... 17.
Syllabus ........................................................................ 21.
Authors Index ............................................................. 53.
Dear Colleagues and Friends,

Ten years ago we were ready to have our 6th Annual Budapest Conference when the news of 9/11 changed the world through terror that was so unnecessary. It seems the world has lost a great deal of innocence. The first thought on that Tuesday morning was that we had to cancel the conference scheduled for September 16-19, 2001. I was already in Budapest in the organizing days of the conference. But, under pressure from the news, I felt the decision could not be made that day and I would make a decision in two days. The following morning, on Wednesday, the world looked so bad that I would have been ready to cancel except that I had made the decision to wait two days. On that second day, Thursday, September 13, I woke up more determined that no terrorist will prevent us from our mission and sent the word out that we are not canceling our meeting. It was truly amazing that the lecturers came through sheer determination and difficulties of travel, not to be prevented from our mission of becoming better physicians. We came from all over Europe and North America, South America, the Middle East and Far East to participate. The participation of our German, British and Spanish colleagues was heart-warming love. Because of their drive, the individuals who have been to Budapest have gotten better and are today making major impact in their local societies, resulting in making patients better.

The fact is clear that physicians who are better trained in the technical procedures are providing better patient care around the world. Over the years we have not only learned how to do procedures but more importantly how to teach them. This year’s tenth anniversary since 9/11 makes us even more determined to become better. I am grateful to every one of you who have become Fellows of Interventional Pain Practice (FIPP). We now have 630 FIPPs worldwide. I especially congratulate the Hungarian section for meeting the required numbers to be a Section. Our local arrangement chairperson, Dr. Edit Racz, has been relentless in her determination to find x-ray machines for us when we needed them, also for going annually to the Ethics Committee in Budapest to represent the Interventional Pain Conference and get permission for us to do our practice sessions. We are grateful for the opportunity that has been awarded us during these years and especially grateful for the permission of Semmelweis University Medical School and the cooperation of all of faculty and staff for use of their facilities.

The leadership of WIP Past President, Dr. Serdar Erdine, MD, FIPP, has been remarkable in bringing more open organizational structure to WIP. The spiritual father of WIP, Prithvi Raj, MD, FIPP, is forever present and it is no small achievement of his to have come up with full tax-exempt approval of the World Institute of Pain Foundation as a charitable organization. We already have our physicians channeling individual patient contributions to the Foundation so that we may help others. The future of the WIP Foundation will bring notable and unimaginable support to deserving people around the world.

The Budapest Conference has always focused on practical and clinically-relevant material. We are interested in safety and efficacy. New and effective pain treatment modalities will be brought to the participants in a setting of morning lectures and afternoon practice of the procedures under expert guidance.

The WIP World Congress this year had to be cancelled in Seoul, Korea because of travelling concerns for so many would-be participants. The Congress is rescheduled to February 4-6, 2012 in Miami Beach, Florida. Please remember this date, a unique opportunity to meet old friends and make new ones, as well as keep abreast of the very latest in our field of study.

Our WIP journal Pain Practice is moving forward with greater and better acceptance and relevance. The Journal will publish the awards for Centers of Excellence. Keep in mind to get your center positioned for this highly coveted award.

The Budapest Conference organizational committee is working hard to make this an outstanding conference again, and we are going to make sure that 2011 will be another memorable experience and conference. Budapest is one of the most beautiful cities in the world. The city is changing for the better. The air is cleaner, the food is outstanding, and the music is fitting for the occasion for you to be a participant in our annual reunion in Budapest.

I have to thank our sponsors that make this annual educational and learning opportunity possible. Our mission simply would not have been possible without the loyal and continuing support of our sponsors. We could not have come this far in such few years. I ask you to note those who sponsor us and make every effort to them.

Please remember that we are not competing with other groups or societies as we all belong to multiple societies. We exist purely because there is a need for activities. Our patients need us to learn in order to improve care we provide them. The WIP is firmly committed to those who wish to teach and those who wish to learn so we can help our patients. Pain knows no boundaries. People in every country need pain doctors who can help them and make the quality of life better worldwide.

In Hungary, we shall watch and listen to the most beautiful starry-eyed children of the Hungarian Folk Dance Group who will show us how dancing should be done. You will be better, and you will make us better by your participation, and your patients will know the difference because your ability will improve through participation. Welcome to Budapest.

Gabor B. Racz, MD, FIPP
Director of Budapest Conference
Past President World Institute of Pain
Co-Director Texas Tech University Health Sciences Center, Lubbock, Texas

Ricardo Ruiz-López, MD, FIPP
President World Institute of Pain
Director Tratamiento del Dolor Clinica del Dolor de Barcelona

GREETINGS

Sciences Center, Lubbock, Texas

Co-Director Texas Tech University Health Sciences Center, Lubbock, Texas

Director of Budapest Conference
Past President World Institute of Pain
Co-Director Texas Tech University Health Sciences Center, Lubbock, Texas
**WIP COUNCIL**

**President WIP**  
Ricardo Ruiz-López, MD, FIPP

**Executive Board**  
Ricardo Ruiz-López, MD, FIPP, Founder and President – Spain  
Serdar Erdine, MD, FIPP, Founder and Immediate Past President – Turkey  
Gabor B. Racz, MD, FIPP, Founder and Past President – USA  
P. Prithvi Raj, MD, FIPP, Founder and Past President – USA  
Charles A. Guel, MD, FRCA, FIPP, FFPMRCA, Honorary Secretary – UK  
Kris C. P. Visser, MD, PhD, FIPP, Honorary Treasurer – The Netherlands  
Craig T. Hartrick, MD, DABPM, FIPP, Editor-in-Chief, Pain Practice – USA  
Miles R. Day, MD, FIPP, DABA, Chair, Board of Examination – USA  
Ira B. Fox, MD, FIPP, Chair, Advisory Board – USA  
José R. Rodríguez Hernandez, MD, FIPP, Chair, Board of Sections – Puerto Rico  
Dianne Willard, Executive Officer – USA

**Section Chairmen**  
Meir Bennun, MD, FIPP – Israel  
Frantz J. Cólimon, MD, FIPP – Colombia  
Peter G. Courtney, MBBS, FIPP – Australia  
Gautam Das, MD, FIPP – India  
Neels de Villiers, MD, FRCA, FIPP – Africa  
Magdi Ramzi Iskander, MD, FFARCS, FIPP – Middle East  
Sang Chul Lee, MD, PhD, FIPP – Korea-Japan-China  
Martin Marianowicz, MD, FIPP – Central-Eastern Europe  
Philippe Mavrocordatos, MD, FIPP – Switzerland  
Patrick R. McGowan, MBChB, FRCA, FIPP, FFPMRCA – UK  
Charles Amaral de Oliveira, MD, FIPP – Latin America  
Nuri Süleyman Özyalçın, MD, FIPP – Turkey  
Mahdi Panah Khahi, MD, FIPP – Iran  
Edvin Koshi, MD, FIPP – Canada  
Teresa Bovaira, MD, FIPP – Spain  
Edit Racz, MD, FIPP – Hungary  
José R. Rodríguez Hernández, MD, FIPP – Puerto Rico  
Andrea M. Trescot, MD, FIPP – USA  
Athina Vadalousa, MD, PhD, FIPP – Mediterranean  
Jan Van Zundert, MD, PhD, FIPP – Benelux  
Alex Sow Nam Yeo, MD, PhD, FIPP – SE Asia

**WIP Examination Board**  
Chair: Miles R. Day, MD, FIPP, DABA  
Co-Chair: Maarten van Kleef, MD, PhD, FIPP  
Liaison to WIP: Serdar Erdine, MD, FIPP  
James E. Heavner, DVM, PhD, FIPP (Hon)  
Charles Amaral de Oliveira, MD, FIPP  
Neels de Villiers, MD, FIPP  
Sang Chul Lee, MD, PhD, FIPP  
Patrick R. McGowan, MBChB, FRCA, FIPP, FFPMRCA  
Jan van Zundert, MD, PhD, FIPP

**Congress Organizers**  
Program Director: Gabor B. Racz, MD, FIPP  
Co-Director: James E. Heavner, DVM, PhD, FIPP (Hon)

**Local Arrangement Committee**  
Chair: Edit Racz, MD, FIPP  
Agnes Stogicza, MD, FIPP  
Lorand Eross, MD, PhD, FIPP

**FACULTY**  
Mert Akbas, MD, FIPP  
Adnan A. Al-Kaisy, MB ChB, FFARCS, FFPMRCA, FIPP  
Ray M. Baker, MD, FIPP  
Hemmo A. Bosscher, MD, FIPP  
Cosimo Bruni, MD  
Kenneth B. Chapman, MD, FIPP  
Serdar Erdine, MD, FIPP  
Lorand Eross, MD, PhD, FIPP  
Joseph D. Fortin, MD  
James E. Heavner, DVM, PhD, FIPP (HON)  
Rafael Justiz, MD, MS, FIPP, DABIPP  
Sang Chul Lee, MD, PhD, FIPP  
Liong Liem, MD, FIPP  
John Nelson, MD, FIPP  
Edit Racz, MD, FIPP  
Gabor B. Racz, MD, FIPP  
Richard Rauck, MD, FIPP  
Olav J. J. M. Rohof, MD, PhD, FIPP  
Murray H. Rosenthal, DO, FAPA  
Ricardo Ruiz-López, MD, FIPP  
Andrea Trescot, MD, FIPP  
Kris C. P. Visser, MD, PhD, FIPP  
Jan Peter Warnke, MD
ACKNOWLEDGEMENTS

The 16th Annual Advanced Interventional Pain Conference and Practical Workshop gratefully acknowledge the following companies for their support of this event:

Boston Scientific
25155 Rye Canyon Loop, Valencia, CA 91355, USA
www.controlyourpain.com
Boston Scientific’s Precision Plus™ SCS System powered by SmoothWave™ Technology blends sophistication and simplicity to deliver life-changing therapy for chronic pain patients. Investing in innovative products, clinical initiatives, and world-class service, Boston Scientific is committed to Making life smoother™ for physicians, patients, and the Neuromodulation community.

CoMedical – Cosman Medical
Gieterijstraat 46, Ridderkerk 2984 AB, Netherlands
CoMedical and Cosman Service Centre is based in Ridderkerk nearby Rotterdam and is a specialized medical company that focuses on development and distribution of Radiofrequency equipment as well specific catheters and needles for the minimal invasive treatment of Chronic Pain and publishing books for pain management. We have an interactive relationship with anesthesiologists, neurosurgeons, pain managers, research and industry. We are exclusive distributor for Cosman Medical, Oakworks and Epimed in the Benelux. Now also are the publisher of the 3rd Edition of Manual of RF Techniques of Dr. Charels A. Gaudi MD, FRCA, FIPP, FRMRA. Since the eightees Enrico Cohen founder and CEO of CoMedical is involved in minimal invasive surgery and specialized on pain management. Since many years he cooperate with Cosman medical (Radionics) now he is also Vice President Sales for Cosman Medical in EAME. CoMedical Team can provide products, training and service for you, your staff and equipment.

Epimed International Inc.
Crossroads Business Park 141 Sal Landrio Drive Johnstown, NY 12095, USA
www.epimedpain.com
Epimed International, inc will be featuring products designed for chronic and acute pain management techniques. We will display the Expanded Line of Racz™ Spring Guide Epidural Catheters, RX™, R.K.™, and FIC Epidural Introducer Needles; R-F™ Line of Radiofrequency Products; Coudé™ & Straight Blunt Nerve Block Needles; and Mini Trays. Also being shown are Radiation Safety Products and Anatomical Models.

Kimberly-Clark Health Care
1400 Holcomb Bridge Road, Roswell, Georgia 30076, USA
www.rfpainmanagement.com
KIMBERLY-CLARK® Pain Management offers a complete line of chronic pain solutions, including an innovative radiofrequency system that features standard, pulsed, and multi-level RF lesioning functions. Our revolutionary cooled-RF technology is designed to treat symptomatic patients experiencing discogenic, sacroiliac, thoracic, and lumbar z-joint pain. Kimberly-Clark’s pain management probes are reusable, durable, and steam-sterilizable. Our radiopaque RF cannulae provide enhanced visualization during positioning. At Kimberly-Clark Health Care, we deliver innovative healthcare solutions that healthcare professionals depend on to meet the demands of a fast-paced world. Our solutions help prevent, diagnose, and manage major issues in Infection Prevention, Digestive Health and Pain Management.

EXHIBITORS AND SPONSORS PROFILES

---

- **Boston Scientific**
- **CoMedical – Cosman Medical**
- **Epimed International Inc.**
- **Kimberly-Clark Health Care**
**GeneRal InFoRma tIon**

**Dates & Venue**
The 16th Annual Advanced Interventional Pain Conference & Practical Workshop  
29 – 31 August, 2011

**Conference Site**
Kempinski Hotel Corvinus Budapest – Regina Ball Room  
H-1051 Budapest, Erzsébet tér 7-8.

**Practical Workshop**
University Labs  
H-1091 Budapest, Üllői út 93.  
Daily bus transfers are provided within the venues.

**The 19th WIP FIPP Examination**  
1 September, 2011  
Venue: University Labs  
H-1091 Budapest, Üllői út 93.

**Conference Website**
www.congressline.hu/pain2011

**Language**
English

**CME Credits**
18 credits were granted by the European Accreditation Council for Continuing Education (EACCME).

**Opening Hours of the Registration Desk at Hotel Kempinski**
- Sunday, 28 August: 14.00 – 19.30
- Monday, 29 August: 07.00 – 13.30
- Tuesday, 30 August: 07.00 – 13.30
- Wednesday, 31 August: 07.00 – 13.30

**FIPP Exam Registration at Kempinski Hotel**
- Wednesday, 31 August: 16.00-19.00

**Registration Fee**
(Regular Fees after 15 July, 2011)
- Pain Conference & Practical Workshop: 1600 Euro  
- Pain Conference: 1150 Euro  
- Accompanying person fee: 350 Euro  
- FIPP Exam registration fee: 2500 USD

**Internet**
Free of charge Wi-Fi service available at the venue.

---

**Medtronic International Trading Sarl**  
Route de Molliau 31, 1131 Tolochenaz, Switzerland  
www.medtronic.com

We’re committed to Innovating for life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. To do that, we’re thinking beyond products and beyond the status quo - to continually find more ways to help people live better, longer.

**Millennium Laboratories Inc.**
16981 Via Tazon, San Diego, CA 92127, USA  
www.milleniumlaboratories.com

Millennium Laboratories, Inc. is research-based medication monitoring company whose test panels, technology, educational resources and scientific experts are specifically focused on clinicians who treat chronic pain. Millennium is the only major Urine Drug Testing (UDT) laboratory exclusively utilizing the latest cutting-edge technology (LC-MS/MS) allowing for the fastest turn-around time in the in the industry.

**St. Jude Medical**
sjmneuro.com

St. Jude Medical Neuromodulation Division develops implantable systems that put more control into the hands of those who treat chronic pain patients. We offer a comprehensive suite of neurostimulation products for the management of chronic intractable pain, exceptional service, technical support, and professional education programs.

**Ziehm Imaging GmbH.**
Donaustrasse 31, 90451 Nuernberg, Germany  
www.ziehm.com

Ziehm Imaging specializes in the development, manufacturing and worldwide marketing of mobile X-ray-based imaging solutions. The company has been market leader in Germany for many years as well as in many other European countries. Today, Ziehm Imaging is a global systems provider, employing over 280 people worldwide. Extensive in-house development know-how is reflected in the Ziehm Imaging C-arms’ high medical imaging performance, intelligent generator technology, significant dose savings and seamless digital network integration. Building on competence and creativity, as well as continuous dialog and close cooperation with renowned universities, research centers and hospitals, Ziehm Imaging has developed groundbreaking technologies that have made the company a global trendsetter in intelligent interventional imaging. Please visit www.ziehm.com for more information.
Commercial Exhibition
The exhibition will be opened from Monday, 29 August until 31 August at the Kempinski Hotel foyer. Delegates will have the opportunity to meet representatives of pharmaceutical and diagnostic equipment companies at their stands to discuss new developments and receive up-to-date product information.

Meals
Coffee breaks, lunches, welcome cocktail and award ceremony dinner are included in the registration fee.

Hotels
Kempinski Hotel Covinus Budapest ***** (Conference venue)
H-1051 Budapest, Erzsébet tér 7-8.
www.kempinski-budapest.com

Hotel Central Basilica***
H-1051 Budapest, Hercegprímás u. 8.
www.hotelcentral-basilica.hu

Official Social Events

Faculty Dinner
Sunday, 28 August, 2011. 20.00-22.00 (only for Faculty Members)
Robinson Restaurant
Dress Code: business casual
Meeting point: Kempinski Hotel lobby at 18.30 (bus transportation is provided).

Welcome Cocktail
Monday, 29 August, 2011, 20.00-22.00 (for all registered guests)
Kempinski Hotel, Regina Ball Room
Programme: Csillagszemű Dance Ensemble
Dress Code: Business casual

Awards Ceremony Dinner
Tuesday, 30 August, 2011, 20.00-23.00 (for all registered guests)
Hungarian Academy of Sciences Ball Room (1014 Budapest, Országház u. 28-30.)
Programme: Award Ceremony and String Quartet
Dress Code: formal
Meeting point: Kempinski Hotel lobby at 19.30 (bus transportation is provided)

Sightseeing Tour in Budapest
Monday, 29 August, 2011, 09.30-13.00
Price: 30 Euro / person (Minimum number of participants: 15 persons)
Including in the accompanying person fee
An approximately 4-hour long sightseeing tour, which shows the most attractive features of the capital. Transportation by bus, with English speaking guide, refreshment and all entrance fees are included.
Meeting point: Kempinski Hotel lobby at 09.15 (conference venue)

Useful Information

How to get to the Conference Venue?
To reach the Conference Venue there are several means of transport:
Metro station “Deák Ferenc Square” station of Metro line 1,2,3.
From the airport to the conference venue use the Airport Minibus Service, fixed rates for passengers
One way: 2990 HUF = cca 12 Euro, Return ticket: 4990 HUF = cca 18 Euro
Tel: +36 1 296 8555 www.airportshuttle.hu or use the PAIN2011 Official Taxi Company:
City Taxi +36 1- 211-1111 (Rate: 5100-5300HUF = cca 23-25Euro).

Climate
The climate of Budapest is continental. In August usually nice warm weather can be expected with a max. temperature of 25-30 °C, while the lowest temperature during the night ranging between 15-20 °C. Nevertheless some rainy days can be expected.

Insurance
The registration fees do not include provision for the insurance of participants against personal accidents, illness, cancellation, theft, property loss or damage. Participants are advised to take adequate personal travel insurance.

Currency
The Forint (HUF), the official national currency, is convertible. The exchange rates applied in Budapest banks, official exchange offices and hotels may vary. All the major credit cards are accepted in Hungary in places displaying the emblem at the entrance.
Exchange rate: 1 Euro = 270 HUF in August, 2011.

Credit Cards
In general, VISA, EC/MC and American Express credit cards are accepted in most restaurants, cafés, shops and petrol stations.

Stores and Shopping
The opening hours of Budapest stores are generally 10.00-18.00 on weekdays and 10.00-13.00 on Saturday. The shopping centers are open from 10.00-21.00 from Monday to Saturday and from 10.00-18.00 on Sunday.

Electricity
The voltage in Hungary is 230V, 50 Hz AC.

Parking
If you drive a personal or rented car, always try to park at a guarded parking lot and do not leave any valuables in the car. Please note, that Budapest is divided into paying areas, with one parking meter in each street. The maximum parking time duration is 2 hours, tariffs may vary.
Detailed Program
MONDAY, 29 August, 2011  Regina Ball Room

07:40  Opening Remarks
Gabor B. Racz, MD, FIPP, Program Director
Ricardo Ruiz-López, MD, FIPP, President of WIP
Edit Racz, MD, FIPP, Chair Local Arrangement Committee

Moderator:  Lorand Eross, MD, PhD, FIPP

07:50  Future of Interventional Pain Practice
Richard Rauck, MD, FIPP

08:30  Percutaneous interventions for trigeminal neuralgia
Serdar Erdine, MD, FIPP

09:00  Intraspinal Drug Delivery
Richard Rauck, MD, FIPP

09:30  Discography
Olav J. J. M. Rohof, MD, PhD, FIPP

10:00  Minimally Invasive Techniques for Discogenic Pain
Ricardo Ruiz-López, MD, FIPP

10:30  Coffee Break

11:00  Vertebral Body Stabilization Techniques
Rafael Justiz, MD, MS, FIPP, DABIPP

11:30  Lysis of Epidural Adhesions: How to Do It and How to Teach it Safely
Gabor B. Racz, MD, FIPP

12:00  RF of Joints and Discs
Olav J. J. M. Rohof, MD, PhD, FIPP

12:30  Sacroiliac Pain
Joseph D. Fortin, MD

13:00  Lunch

13:30  Transport to University
Labs Afternoon workshops

Detailed Program
TUESDAY, 30 August, 2011  Regina Ball Room

Moderator:  Mert Akbas, MD, FIPP

08:00  Complications of Interventional Pain Therapy
John Nelson, MD, FIPP

08:30  Epidural Injections
Kris C. P. Vissers, MD, PhD, FIPP

09:00  Imaging for Interventional Pain Management
Joseph D. Fortin, MD

09:30  Controversies in the Diagnosis of Painful Lumbar Disc Degeneration
Ray M. Baker, MD, FIPP

10:00  Joint Pain and Its Treatment with Biological Agents and Drugs
Cosimo Bruni, MD

10:30  Coffee Break

11:00  Lumbosacral Spinal Endoscopy Round Table
Moderator:  Gabor B. Racz, MD, FIPP
Science Background – James E. Heavner, DVM, PhD, FIPP (HON)
Clinical Perspective – Hemmo A. Bosscher, MD, FIPP
Application to Arachnoiditis – Jan Peter Warnke, MD

12:00  Cold Allodynia, Nerve Entrapment Radiculopathies and Illusions
The Science – James E. Heavner, DVM, PhD, FIPP (HON)
The Clinical – Gabor B. Racz, MD, FIPP

12:30  Lunch

13:30  Transport to University
Labs Afternoon workshops
Detailed Program

WEDNESDAY, 31 August, 2011  Regina Ball Room

Moderator: Kenneth B. Chapman, MD, FIPP

08:00  Management of Spinal Stenosis
John Nelson, MD, FIPP

08:30  Pathophysiology and Pharmacologic Management of Neuropathic Pain
Andrea Trescot, MD, FIPP

09:00  Pharmacologic Management of Cancer Pain
Kris C. P. Vissers, MD, PhD, FIPP

09:30  Current Neurosurgical Approaches to the Treatment of Pain
Lorand Eross, MD, PhD, FIPP

10:00  Facial Pain and Cervicogenic Headache
Liong Liem, MD, FIPP

10:30  Coffee Break

11:00  Ultrasound Guided Treatment
Sang Chul Lee, MD, PhD, FIPP

11:30  Sacral Nerve Root Stimulation – Recent Advances
Gabor B. Racz, MD, FIPP

12:00  High Frequency Spinal Cord Stimulation in the Management of Axial Back Pain
Adnan A. Al-Kaisey, MB, CHB, FRCA, FPMRCA, FIPP

12:30  Urine Drug Screening
Murray H. Rosenthal, DO, FAPA

13:00  Lunch

13:30  Transport to University
Labs Afternoon workshops

FIPP Awards Ceremony

TUESDAY, 30 August, 2011, at 20:00

Master of Ceremonies: Miles Day, MD, FIPP; DABA
Opening Remarks – Local Organizing Committee
Edit Racz, MD, FIPP
Agnes Stogicza, MD, FIPP
Lorand Eross, MD PhD, FIPP

The First Ten Years of FIPP
P. Prithivi Raj, MD, FIPP, WIP Founder & Past President

Presentation of Certificates to Fellows of Interventional Pain Practice (FIPP)
WIP Board of Examination Members

FIPP Class of 2 September, 2010 – Budapest, Hungary

602 Aertssen, Jack, MD, FIPP  The Netherlands
603 Bhatia, Anuj, MBBS DNB MD FRCA MNAMS FFP MRCA, FIPP  Canada
604 Blau, Jonathan, MD, FIPP  USA
605 Cada, Miroslav, MD, FIPP  Austria
606 Canty, Tim, MD, FIPP  USA
607 Deshmukh, Prakash, MD, FIPP  India
608 Dirckx, Veerle, MD, FIPP  Belgium
609 Du Plessis, Pauline, MD, FIPP  South Africa
610 Filipppini-de Moor, Gertruda, MD, FIPP  The Netherlands
611 Gautam, Sujeet Kumar Singh, MD, FIPP  India
612 Goswami, Subrata, MBBS, FIPP  India
613 Haghshenas, Seyed Mohammad, MBBS, FIPP  Iran
614 Hussain, Assad, MBBS, FHKCA, FANZCA, Dip Pain Mgt (Hkca), FFP, MANZCA, FIPP  Iran
615 Kal, Jasper Emiel, MD, PhD, FIPP  The Netherlands
616 Kanthed, Pravesh, MBBS, DA, DNB, FIPP  India
617 Laverdière, Mélanie, MD, FIPP  Switzerland
618 Lim, Kyung-Joon, MD, PhD, FIPP  South Korea
619 Mestrum, Roel, HM, MD, FIPP
620 Mishriqy, Basem Henry Habib, MD, FIPP
621 Naderi -Nabi, Bahram, MD, FIPP
622 Nimmakayalu Sampu, Swaroop, FCARCSI FIPP
623 Perumal, Muralitharan, MD, FIPP
624 Phua, Darren Shingkuan, MD, FIPP
625 Ray, Subrata, DA, FIPP
626 Reddy, Raja Varadapura, MD, FRCA, FFPMRCA, FIPP
627 Shanthanna, Harsha, MD, DNB, FIPP
628 Sie, Robert Bernhard, MD, FIPP
629 Soin, Amol, MD, FIPP
630 Tay, Teik Guan, MBBS, FIPP

645 Perez-Martinez, Jordi, MD, PhD, FIPP

621 Naderi -Nabi, Bahram, MD, FIPP
622 Nimmakayalu Sampu, Swaroop, FCARCSI FIPP
623 Perumal, Muralitharan, MD, FIPP
624 Phua, Darren Shingkuan, MD, FIPP
625 Ray, Subrata, DA, FIPP
626 Reddy, Raja Varadapura, MD, FRCA, FFPMRCA, FIPP
627 Shanthanna, Harsha, MD, DNB, FIPP
628 Sie, Robert Bernhard, MD, FIPP
629 Soin, Amol, MD, FIPP
630 Tay, Teik Guan, MBBS, FIPP

FIPP Class of 25 June, 2011 – Maastricht, The Netherlands

631 Annehmohammadzadeh, Haligaldy, MD, FIPP
632 Balthasar, Andrea Johanna, MD, FIPP
633 Dakeel, Raad, MD, FIPP
634 Husada, Satria, MD, FIPP
635 Janssen, Markus, MD, FIPP
636 Joseph, A. Alistair, FCARCSI, FIPP
637 Kallewaard, Jan-Willem, MD, FIPP
638 Köder, Brigitte, MD, FIPP
639 Lim, Tai Chuan, MD, FIPP
640 Mehta, Palak Bhavin, MD, FIPP
641 Meyer, Johannes, MD, FIPP
642 Munshi, Shirazahmed Mo.Abbas, MD, FIPP
643 Oberholzer, Andries Johannes, MD, FIPP
644 Patel, Anant Gunvantbhai, MD, FIPP
645 Perez-Martinez, Jordi, MD, PhD, FIPP

646 Rouwet, Edward, MD, FIPP
647 Sahinler, Bolkar E., MD, FIPP
648 Dongen, Vincent Ran, MD, FIPP
649 Wilson, Eric, MB, BCH, FIPP

Annehmohammadzadeh, Haligaldy, MD, FIPP
Balthasar, Andrea Johanna, MD, FIPP
Dakeel, Raad, MD, FIPP
Husada, Satria, MD, FIPP
Janssen, Markus, MD, FIPP
Joseph, A. Alistair, FCARCSI, FIPP
Kallewaard, Jan-Willem, MD, FIPP
Köder, Brigitte, MD, FIPP
Lim, Tai Chuan, MD, FIPP
Mehta, Palak Bhavin, MD, FIPP
Meyer, Johannes, MD, FIPP
Munshi, Shirazahmed Mo.Abbas, MD, FIPP
Oberholzer, Andries Johannes, MD, FIPP
Patel, Anant Gunvantbhai, MD, FIPP
Perez-Martinez, Jordi, MD, PhD, FIPP
Rouwet, Edward, MD, FIPP
Sahinler, Bolkar E., MD, FIPP
Dongen, Vincent Ran, MD, FIPP
Wilson, Eric, MB, BCH, FIPP

Annehmohammadzadeh, Haligaldy, MD, FIPP
Balthasar, Andrea Johanna, MD, FIPP
Dakeel, Raad, MD, FIPP
Husada, Satria, MD, FIPP
Janssen, Markus, MD, FIPP
Joseph, A. Alistair, FCARCSI, FIPP
Kallewaard, Jan-Willem, MD, FIPP
Köder, Brigitte, MD, FIPP
Lim, Tai Chuan, MD, FIPP
Mehta, Palak Bhavin, MD, FIPP
Meyer, Johannes, MD, FIPP
Munshi, Shirazahmed Mo.Abbas, MD, FIPP
Oberholzer, Andries Johannes, MD, FIPP
Patel, Anant Gunvantbhai, MD, FIPP
Perez-Martinez, Jordi, MD, PhD, FIPP
Rouwet, Edward, MD, FIPP
Sahinler, Bolkar E., MD, FIPP
Dongen, Vincent Ran, MD, FIPP
Wilson, Eric, MB, BCH, FIPP

Annehmohammadzadeh, Haligaldy, MD, FIPP
Balthasar, Andrea Johanna, MD, FIPP
Dakeel, Raad, MD, FIPP
Husada, Satria, MD, FIPP
Janssen, Markus, MD, FIPP
Joseph, A. Alistair, FCARCSI, FIPP
Kallewaard, Jan-Willem, MD, FIPP
Köder, Brigitte, MD, FIPP
Lim, Tai Chuan, MD, FIPP
Mehta, Palak Bhavin, MD, FIPP
Meyer, Johannes, MD, FIPP
Munshi, Shirazahmed Mo.Abbas, MD, FIPP
Oberholzer, Andries Johannes, MD, FIPP
Patel, Anant Gunvantbhai, MD, FIPP
Perez-Martinez, Jordi, MD, PhD, FIPP
Rouwet, Edward, MD, FIPP
Sahinler, Bolkar E., MD, FIPP
Dongen, Vincent Ran, MD, FIPP
Wilson, Eric, MB, BCH, FIPP

Annehmohammadzadeh, Haligaldy, MD, FIPP
Balthasar, Andrea Johanna, MD, FIPP
Dakeel, Raad, MD, FIPP
Husada, Satria, MD, FIPP
Janssen, Markus, MD, FIPP
Joseph, A. Alistair, FCARCSI, FIPP
Kallewaard, Jan-Willem, MD, FIPP
Köder, Brigitte, MD, FIPP
Lim, Tai Chuan, MD, FIPP
Mehta, Palak Bhavin, MD, FIPP
Meyer, Johannes, MD, FIPP
Munshi, Shirazahmed Mo.Abbas, MD, FIPP
Oberholzer, Andries Johannes, MD, FIPP
Patel, Anant Gunvantbhai, MD, FIPP
Perez-Martinez, Jordi, MD, PhD, FIPP
Rouwet, Edward, MD, FIPP
Sahinler, Bolkar E., MD, FIPP
Dongen, Vincent Ran, MD, FIPP
Wilson, Eric, MB, BCH, FIPP

Annehmohammadzadeh, Haligaldy, MD, FIPP
Balthasar, Andrea Johanna, MD, FIPP
Dakeel, Raad, MD, FIPP
Husada, Satria, MD, FIPP
Janssen, Markus, MD, FIPP
Joseph, A. Alistair, FCARCSI, FIPP
Kallewaard, Jan-Willem, MD, FIPP
Köder, Brigitte, MD, FIPP
Lim, Tai Chuan, MD, FIPP
Mehta, Palak Bhavin, MD, FIPP
Meyer, Johannes, MD, FIPP
Munshi, Shirazahmed Mo.Abbas, MD, FIPP
Oberholzer, Andries Johannes, MD, FIPP
Patel, Anant Gunvantbhai, MD, FIPP
Perez-Martinez, Jordi, MD, PhD, FIPP
Rouwet, Edward, MD, FIPP
Sahinler, Bolkar E., MD, FIPP
Dongen, Vincent Ran, MD, FIPP
Wilson, Eric, MB, BCH, FIPP
Big things come in small packages.

With its all-in-one design, Ziehm Solo is one of the most compact and versatile C-arms for crowded treatment scenarios.

Equipped with state-of-the-art imaging technology, this C-arm delivers great performance for orthopedics, traumatology, pain management and other applications. Versatile viewing options enable you to configure the unit according to your needs and local conditions. All this at a competitive price.

→ For more information visit www.ziehm.com
SERDAR ERDINE, MD, FIPP

BIOGRAPHICAL SKETCH
Prof. Serdar Erdine MD,FIPP is the immediate past president of WIP and CEO of the World Institute of Pain Foundation. He is the chairman of the Istanbul Pain Center affiliated with Istanbul Bilim University.

PERCUTANEOUS INTERVENTIONS FOR TRIGEMINAL NEURALGIA

Objectives
Upon completion of this presentation attendees will be able to discuss:

- What sets percutaneous interventions for trigeminal neuralgia apart from other interventional pain therapies
- The rationale for performing percutaneous interventions for trigeminal neuralgia
- Indications for each percutaneous intervention for trigeminal neuralgia
- Expected outcomes of percutaneous interventions for trigeminal neuralgia
- Complications of percutaneous interventions for trigeminal neuralgia
- State of the art for percutaneous interventions for trigeminal neuralgia

Key Points
Definition of a good result is not easy
- Variation of the follow-up also affects the decision making
- Learning curve-experience is important
- No method is curable
- Cure is unpredictable, recurrence rate is predictable
- All techniques have advantages and disadvantages
- RF is still the preferred technique
- It is less morbidity more cost effective then open techniques
- Glycerol causes mild complications, less effective
- Balloon causes mild sensorial loss
- Recurrence rate for open techniques may be similar

References

OLAV J. M. ROHOF, MD, PHD, FIPP

BIOGRAPHICAL SKETCH
Dr. Olav Rohof (04-06-1950) MD, PhD, FIPP is an anesthesiologist and interventional pain specialist, and head of the pain clinic of Orbis Medical Center in Sittard Geleen, the Netherlands.

As an anesthesiologist he has been working full time in the pain clinic since 1989. He has trained many colleagues from all over the world.

He has special interest and experience in trigeminal neuralgia and facial pain, back pain, neck pain and headache, treatment of joints and CRPS. In 2002 he wrote his thesis on the RF treatment of the ganglion Gasser in trigeminal neuralgia (University of Bonn Germany).

DISCOGRAPHY

Objectives
Upon completion of this presentation attendees will be able to discuss:

1. Definitions: Disc stimulation, Discography, provocative discography, disc manometry
2. Patient selection, in- and exclusion criteria
3. Procedure and technique
4. The level(s) to be tested?
5. In disc stimulation use of disc manometry is advised, if available
6. Evaluation of results of disc stimulation and discography
7. Complications
8. Differential Diagnosis
9. Discography still indicated?
10. Results of a prospective pilot study of pulsed RF disc treatment in the nucleus following lumbar discography

Key points:
- Definitions
  - Disc stimulation: a procedure developed to define a painful intervertebral disc by intradiscal injection.
  - Discography: injection of dye to describe the internal disc morphology.
  - Provocative Discography: a combination of both of the above.
  - Disc manometry: disc stimulation with intradiscal pressure measurement.
  - Only to be used when intervensional treatment for reduction of discogenic pain is considered.
- Procedure and technique will be presented.
- Combination of history, physical examination and additional examinations (MRI, EMG, CT) determines the probably involved levels to be tested.
- A suspected normal level functions as control level.
- Disc manometry, technique and criteria will be discussed (2,3)
- Evaluation of results of disc stimulation will be discussed according to ISIS and IASP criteria.
- Evaluation of discography using the Dallas Discogram Scale (5)
- Discitis is the mostly feared complication, prophylactic use of antibiotics is advised in
- international guidelines, intravenously or intradiscally, in the “two needle technique” questionable (4)

References
1. 10. Results of a prospective pilot study of pulsed RF disc treatment in the nucleus following lumbar discography


• DD: trauma, fracture, tumour, infection, neurologic disease, visceral pain
• Despite controversial literature lumbar (provocative) discography and disc manometry still is the gold standard for confirming the diagnosis discogenic pain. A strong patient selection is needed to improve the results of invasive intradiscal treatments.
• Technique and results of a prospective pilot study of Pulsed RF disc treatment in the nucleus following lumbar discography

References

Further relevant literature:

Additional literature to be posted on the website

Ricardo Ruiz-López, MD, FIPP

BIOPGRAPHICAL SKETCH
Ricardo Ruiz-López, MD, Neurosurg., FIPP, is Director of Barcelona Spine and Pain Institute (Institut de Columna Vertebral / Clinica del Dolor de Barcelona), Executive Member of the Board of Directors of Hospital Delfos (Barcelona) and CEO Project for Barcelona Spine & Pain Surgery Clinic.

After receiving his MD degree from the University of Madrid in 1975 and the Board of Neurosurgery in 1980, he founded in 1986 Clinica del Dolor de Barcelona. His major areas of scientific interest are the Neurosurgery of Pain, the Interventional Techniques and Surgery for Spinal Chronic Pain Conditions, and the development of new organizational models for Patient’s Care.

Editor of a number of medical journals, he has published extensively on Pain Management and Interventional Pain Therapies.

He is a Founding Member of various National and International Medical Societies on the Pain Field, and Visiting Professor and Lecturer at European and American Universities.

President of the Organizing Committee of the II EFIC Congress (European Federation of IASP Chapters) “Pain in Europe” Barcelona, September 1997 and of the 3rd World Congress on Pain of WIP (World Institute of Pain), Barcelona, September 2004.

President of World Institute of Pain (WIP) 2011-2014, President of the Catalan Pain Society (Catalonia, Spain) 2006-2010, and Permanent Trustee of the World Institute of Pain Foundation, NC, USA.

MINIMALLY INVASIVE TECHNIQUES FOR DISCOGENIC PAIN

Minimally invasive spine surgery has evolved rapidly within the last two decades in an effort to decrease morbidity associated with open procedures.

Low back pain of discogenic origin is a highly prevalent condition. Internal disc disruption has been described as the internal disruption of disc architecture of the disc without signs of disc protrusions or without positive signs for nerve root compression. Tears that appear in the layers of the annulus fibrosus allow nuclear material to irritate sensitive sinu-vertebral nerve-endings. Concentric annular tears and rim lesions are often present. The modified Dallas discogram classification is now the gold standard for the computer tomography (CT) classification of annular tears. It classifies discal lesions into five possible severities of the radial annular tear. Provocation discography is the most accurate diagnostic procedure, with two components to it: an attempt to reproduce the patient’s pain by injecting contrast material into the disc, and to perform a painless discogram in the adjacent disc. Gadolinium-enhanced magnetic resonance imaging is an alternative to CT discogram.

There are several therapeutic options for discogenic pain, ranging from conservative management to open surgery. In this review we described most percutaneous techniques that are currently being used to treat discogenic pain with and without disc herniation, as well as some of the emerging minimally invasive surgery techniques for disc removal.

References
RAFAEL JUSTIZ, MD, MS, FIPP, DABIPP

BIOGRAPHICAL SKETCH
Dr. Rafael Justiz is currently the Director of Interventional Pain Management, Department of Neurosciences, Saint Anthony’s Hospital, Oklahoma City, Oklahoma.

Dr Justiz earned a Bachelor and Masters in Sciences from Florida International University in Miami, Florida, and his Doctor of Medicine from Medical college of Wisconsin. He completed his anesthesia residency at the University of South Florida in Tampa, and received his fellowship in Interventional Pain Management at Texas Tech University in Lubbock, Texas. Dr. Justiz joined the faculty at the international pain institute at University Health Sciences Center and now is currently in private practice.

He is board-certified in anesthesiology by the American Board of Anesthesiology and has Added Qualifications in Pain Management by the same board. He also holds the WIP Fellow in Interventional Pain Practice certification (FIPP) and is a Diplomate of the American Board of Interventional Pain Physicians (ABIPP).

Dr Justiz has published several book chapters and journal articles. His areas of interest’s include peripheral field/spinal cord stimulation and treatment of refractory head and facial pain.

VECTRELL BODY STABILIZATION TECHNIQUES

Objectives
Upon completion of this presentation attendees will be able to discuss

- Osteoporosis
- Treatment options for osteoporosis
- Vertebral Augmentation
- Identify patient and workup
- Different Techniques
- How to perform vertebral augmentation
- Complications

Key Points

- Discuss osteoporosis including risk factors, epidemiology, its economic effects and clinical consequences. Look at the guidelines for determining osteoporosis, and be able to recognize the disease process and what treatment options there are available.
- Discuss ideal patient selection and workup, and define fracture configurations.
- Discuss different imaging modalities that can be used and their differences.
- Discuss how vertebral augmentation reduces pain and what mechanism is involved.
- Look at the indications, contraindications and relative contraindications involved with vertebral augmentation.
- Discuss the different techniques employed in vertebral body augmentation, transpedicular and extrapedicular approaches. Look at the anatomical landmarks and proper imaging technique for safety. In detail define how each technique is performed and the approaches that can be employed including proper trajectory and vertebral access.
- Recognize the common complications and practice safe techniques to avoid these complication

References

OLAV J. M. ROHOF, MD, PHD, FIPP

(PULSED) RF TREATMENT OF DISC AND JOINTS

Objectives
Upon completion of this presentation attendees will be able to discuss:

1. An overview of RF and PRF disc treatment techniques (1)
2. Treatment of articular pain in small and large joints (2)
3. Causes of articular pain, prevalence, pathophysiology (5)
4. New technique of PRF treatment of the Lateral Atlanto Axial (LAA) joint (6)
5. Results of 1 yr follow up of first 100 cases of PRF AA joint treatment (5) (7)
6. Results PRF treatment Knee, shoulder, trapezio-metacarpal, and hallux valgus (2)
7. Shoulder treatment with PRF supraspacular nerve, on indication combined with the one entry – 3 compartment block.

Key points
1. There is equivocal evidence about RF heating techniques of the disc, a prospective pilot study of PRF disc treatment shows promising results, but this should be confirmed in a randomised study.
2. Osteoarthritis (OA) is the most common type of joint disease (22% of the adult population), pain is the major symptom determining functional loss; there is a poor correlation between pain and radiological changes; Infiltration with steroids are short lasting (3)
3. Pulsed RF treatment of small joints like the lateral AA joint without any injection is more accessible in the supine position with a true lateral fluoroscopic approach, and has remarkable relatively long-lasting results. (4, 5)
4. Diagnostic tools: History, clinical examination, radiology, blood tests and biomarkers. (6)
5. Approaches for PRF treatment of the knee, shoulder, trapezio-metacarpal and metatarso-hyalngeal joints will be presented.
6. Results of PRF treatment (2) will be presented.
7. Small joints respond particularly well to PRF treatment.
8. Results of PRF treatment of Shoulder and Knee joints are superior to steroid infiltrations.
9. Discussion: PRF treatment of large joints combined with viscosupplementation with hyaluronic acid, but without corticosteroids.

Upon completion of this presentation attendees will be able to discuss:

1. Treatment of articular pain in small and large joints (2)
2. Causes of articular pain, prevalence, pathophysiology (5)
3. New technique of PRF treatment of the Lateral Atlanto Axial (LAA) joint (6)
4. Results of 1 yr follow up of first 100 cases of PRF AA joint treatment (5) (7)
5. Results PRF treatment Knee, shoulder, trapezio-metacarpal, and hallux valgus (2)
6. Shoulder treatment with PRF supraspacular nerve, on indication combined with the one entry – 3 compartment block.

Literature
5. Rohof OJJM. PRF treatment of the Lateral AA joint , one year follow up of first 100 cases with a true lateral approach. (personal communication, WIP London June 2009)
Epiducer™
Lead Delivery System

Industry-first Lead Delivery System
FOR UNPRECEDENTED ACCESS
TO LEAD OPTIONS.

St. Jude Medical’s Epiducer lead delivery system is the next generation in epidural access. This revolutionary system allows introduction of a unique class of paddle leads as well as multiple lead arrays through a single percutaneous entry point. With unparalleled options and reduced procedural complexity, the Epiducer system is redefining percutaneous procedures.

sjmneuro.com

JOSEPH D. FORTIN, MD

BIOGRAPHICAL SKETCH
Dr. Fortin is Medical Director of Spine Technology and Rehabilitation and Clinical Professor of Indiana University School of Medicine, Fort Wayne, Indiana.

SACROILIAC PAIN 2011

Objectives
Upon completion of this presentation attendees will be able to discuss:

- The unique anatomical and biomechanical features of the sacroiliac joint.
- Key clinical features of patient presenting with symptomatic sacroiliac joints.
- Diagnostic evaluation of SIJ dysfunction.
- Rehabilitation of SIJ dysfunction.
- Interventional techniques for addressing SIJ pain.

Key Points
- The sacroiliac joint is a putative source of low back pain and sciatica. The prevalence of sacroiliac joint dysfunction is between two and thirty percent.
- The SIJ is a true synovial joint with hyaline cartilage on the sacral side and fibrocartilage on the iliac side. The articular surfaces have numerous interdigitating ridges and depressions.
- The ventral ligaments are a thin extension of the capsule and the dorsal ligaments are a series of discontiguous bands.
- Mechanically, the sacroiliac joint is a relay station transmitting loads to and fro the trunk and lower extremities.
- Histological analysis of the sacroiliac joint has verified the presence of nerve fibers within the joint capsule and joint ligaments. While the levels of innervation and divisions of SIJ innervation have been the subject of debate. A fetal correlate study found no receptors in the ventral capsule and concluded that the SIJ is innervated by the sacral dorsal rami.
- No physical exam findings are unequivocally pathognomonic of sacroiliac joint pain. The Fortin Finger Test is a reliable indicator of sacroiliac joint pain, yet it lacks sensitivity.
- Controlled diagnostic blocks appear to be the sole direct method of distinguishing symptomatic versus asymptomatic sacroiliac joints.
- Rehabilitative measures include manual medicine techniques, pelvic stabilization exercise to allow dynamic postural control, and muscle balancing of the trunk and lower extremities.
- Interventional techniques include image-guided intra-articular steroid injections, radiofrequency neurotomy, cryotherapy, prolotherapy, and fusion. There is a paucity of controlled trial on any treatment measure.

References
Additional references to be posted on the website.


Recommended literature

* of special interest
** of outstanding interest

RAY M. BAKER, MD, FIPP

BIOPGRAPHICAL SKETCH
Dr. Baker is a Clinical Professor of Anesthesiology (adjunct) at the University of Washington. He is the Immediate Past President of the North American Spine Society and the incoming President of the International Spine Intervention Society.

CONTROVERSIES IN THE DIAGNOSIS OF PAINFUL LUMBAR DISC DEGENERATION 2011

Objectives
Upon completion of this presentation attendees will be able to discuss:
- The definition and key features of a diagnostic criterion standard
- The role of advanced imaging in the diagnosis of painful lumbar disc degeneration (DD)
- The role of the history and physical examination in the diagnosis of painful lumbar DD
- The role of provocation discography in the diagnosis of painful lumbar DD
- Controversies in the diagnosis of painful lumbar DD, including:
  - The limitations of provocation discography
  - The potential risks of provocation discography
  - The link between provocation discography and expensive treatments, especially lumbar fusion
- The potential role of novel technologies in the diagnosis of painful lumbar DD

Key Points
- Utilizing the Sackett and Haynes definition of a criterion standard, there exists no Gold Standard for the diagnosis of painful lumbar DD.
- Advanced imaging is helpful in excluding patients with normal MRIs from the diagnosis of painful lumbar DD.
- Compared with provocation discography, MRI loss of signal intensity, high intensity zones, and end-plate (Modic) changes are modestly helpful at best (+LR 3) in diagnosing patients with painful lumbar DD.
- The history and physical examination are of limited utility in diagnosing patients with painful lumbar DD.
- Provocation discography is still a controversial test for painful lumbar DD. There is no ability to compare it with a criterion standard, there is a high false positive rate in patients with certain co-existing conditions, and it has been linked to poor outcomes from lumbar fusion surgery. Recent studies have also raised the possibility that disc puncture might accelerate disc degeneration.
- Limited evidence supports novel technologies in the diagnosis of painful lumbar DD, including MR Spectroscopy.

References
JOINT PAIN AND ITS TREATMENT WITH BIOLOGICAL AGENTS AND DRUGS

Objectives
Upon completion of this presentation attendees will be able to discuss:

- The importance of pain in rheumatic diseases
- The role of cytokines in inflammation and pain
- How to assess joint pain in daily practice
- How to assess disease activity in Rheumatoid Arthritis
- Biological therapy and Target therapy
- Effects of TNF-α inhibitors on pain during RCTs
- The comparison between Biological drugs and DMARDs
- Goals of therapy in Rheumatic diseases

Key Points
- Pain is one of the main features of rheumatic diseases and its management is an area of increasing research.
- Pain in rheumatic diseases is strictly connected with inflammation, whose pathogenesis depends on many cytokines as TNF-α, IL-1β and IL-6, which have also a very important role in the maintenance of pain and in the CNS.
- Old drugs like DMARDs are able to control mainly inflammation, with a minor effect on disability and bone damage.
- It’s important to assess Pain in daily practice and it is also a parameters of the Disease Activity Score (DAS), which is the best index to assess disability too.
- Biological drug are produced using biotechnology and are directed against specific cytokines or molecular pathways: this is the so-called Target Therapy.
- The first biological drugs were TNF-α inhibitors, which proved to be effective in reducing pain, improving quality of life and managing disease activity in RA and other rheumatic and non-rheumatic diseases, as shown by many RTCs.
- In rheumatological diseases the sooner the therapy is started, the better the disease activity is controlled, as patients seem to be more prone to favourable treatment outcome during the very start of the disease.

References
LUMBOSACRAL SPINAL ENDOSCOOPY ROUND TABLE

SCIENCE BACKGROUND: JAMES E. HEAVNER, DVM, PHD, FIPP (HON)
CLINICAL PERSPECTIVE: HEMMO A. BOSSCHER, MD, FIPP
APPLICATION TO ARACHNOIDITIS: JAN PETER WARNKE, MD

Objectives
Upon completion of this round table presentation attendees will be able to discuss
• Key developments leading to the use of flexible endoscopes in the spinal canal
• Primary reasons for performing spinal endoscopy
• Indications and techniques for performing epiduroscopy and thecaloscopy
• How patients benefit from spinal canal endoscopy

Key Points
• Advent of small, flexible fiberscopes and suitable light sources, as well as techniques to introduce scopes into the spinal canal is the foundation for spinal endoscopy
• Spinal canal endoscopy provides direct viewing of structures within the canal thereby aiding in determination of abnormalities involved in chronic low back pain and/or pain radiating to the lower extremities
• Spinal canal endoscopy allows direct therapeutic intervention while viewing sources of pain
• Spinal canal endoscopy may identify causes of pain that cannot be determined by physical examination and imaging (CT scan, MRI)
• Major surgical intervention can often be avoided by using minimally invasive spinal canal endoscopy.

References

COLD ALLODYNIA, NERVE ENTRAPMENT, RADICULOPATHIES AND ILLUSIONS: THE SCIENCE AND THE CLINICAL

THE SCIENCE: JAMES E. HEAVNER, DVM, PHD, FIPP (HON)
THE CLINICAL: GABOR B. RACZ, MD, FIPP

Objectives
Upon completion of this round table presentation attendees will be able to discuss
• Cold allodynia and hyperalgesia as frequent clinical findings in patients with neuropathic pain
• Mechanisms and nerve pathways implicated in cold allodynia and hyperalgesia
• Case examples of cold allodynia and hyperalgesia in patients with neuropathic pain
• Therapies – what works, what does not work and why

Key Points
• Cold allodynia and hyperalgesia are associated with injuries to both the central and peripheral nervous systems
• In general, little is known about mechanisms of cold allodynia and hyperalgesia. NMDA-receptor mediated central sensitization is involved in cold hyperalgesia but other mechanisms are also present
• The normal human brain can be tricked to perceive cold allodynia (thermal grill illusion) which might provide clues to how nerve injury produces cold allodynia and hyperalgesia
• Sympathetic block may relieve cold allodynia/hyperalgesia, but may not be successful if the block is not complete

References
PATHOPHYSIOLOGY AND PHARMACOLOGIC MANAGEMENT OF NEUROPATHIC PAIN

Objectives
- Upon completion of this presentation, attendees will be able to discuss:
  - Some of the common causes of peripheral neuropathy
  - Some of the common pharmacologic and nonpharmacologic treatments of peripheral neuropathy
  - Some of the new directions in the treatment of peripheral neuropathy

Key points
- Peripheral neuropathy is not a homogeneous process, but rather encompasses a large, diverse group of nerve pathologies.
- There are multiple causes of peripheral neuropathy.
- Although diabetes is the most common cause of peripheral neuropathy, most cases of peripheral neuropathy never have a defined etiology.
- Most of the treatments are pharmacologic, but there are increasingly options for interventional treatment.

PHARMACOLOGICAL MANAGEMENT OF CANCER PAIN

Objectives
At the end of this presentation attendees will be able to discuss:
- The value of following the WHO pain ladder in the management of cancer pain
- The role of adjuvant treatment such as antidepressants and anti-epileptics
- The appropriate use of breakthrough medication
- The control of side effects and complications
- The role of palliative cancer treatments such as chemotherapy and bisphosphonates
- The right dose calculation for an opioid switch

Key points
- The management of cancer pain requires a multidisciplinary and multifactorial approach. The treatment may consist of tumor oriented interventions supplemented with symptomatic pain management.
- The most important step in reaching an adequate pain control in patients with cancer is a good understanding of the underlying pain mechanism, in order that the right treatment can be chosen.
- The first step in pain treatment is antitumor therapy by the medical oncologist if indicated.
- In case of pain caused by bone metastases, bisphosphonates may be considered.
- Basic pharmacological treatment aims at achieving constant steady state plasma levels, which is preferentially achieved by long-acting formulations.
- Patients should be instructed to use immediate release preparations for control of breakthrough pain.
- The use of step two of the WHO pain ladder is no longer recommended.
- Only weak recommendation can be used to support combination step three opioid therapy.
- There is evidence to support the efficacy and tolerability of hydromorphone for moderate to severe cancer pain as an alternative to morphine and oxycodone.
- Alternative administration routes to oral opioids such as parenteral, transdermal and rectal administration may be considered. There is no significant difference in efficacy or side effects between administration routes.
- There is a weak recommendation for using spinal opioids in adult patients with cancer.
- In case of tolerance or severe side effects on opioid analgesics, opioid switch is recommended.
- When opioid therapy is started it is recommended to prescribe osmotive laxatives.
- Vomiting and nausea may be controlled by prokinetics and dopamine antagonists.
- There is direct clinical evidence in cancer-related pain and renal impairment is insufficient to allow formulation of guidelines. The risk of opioid use is stratified according to the activity of opioid metabolites and potential for accumulation. Fentanyl, alfentanil and methadone are the least likely to cause harm when used appropriately. Morphine may be associated with toxicity in patients with renal impairment.
- The role of adjuvant therapy (e.g. antidepressants and anti-epileptics) has become evident when neuropathic characteristics are present.
- Side effects of the central nervous system caused by opioid analgesics, such as sedation and hallucinations, may wear off over time.
- Delirium, myoclonus and hyperalgesia may be controlled by opioid switching.
- For the management of opioid intoxication opioid antagonists such as naloxone are recommended.
- Recently, opioid antagonists, that do not cross the blood brain barrier have been developed. Simultaneous use of those antagonists and opioids may prevent gastro-intestinal side effects.
Recommended literature
* of special interest
** of outstanding interest


Chemotherapy


Biphosphonates


Weak opioids


Strong opioids


Opioid rotation
15. ** Vissers KC, Besse K, Hans G, Devulder J, Morlion B. Opioid Rotation in the Management of Chronic Pain: Indications for drezotomy includes 1. Cancer pain that is limited to the armamentarium of pain surgery. Surgery in the DREZ must be considered within the frame of all the methods belonging to the armamentarium of pain surgery.

Midline myelotomy: Gildenberg and Hirschberg (1984) performed myelotomy for visceral pain with excellent results in 8 out of 12 patients. Punctuate midline myelotomy after laminecetomy at T8 level for malignant visceral pain found efficient by Nauta et al. (2000). This technique has limited indication today.

Anterior Cordotomy: The ideal candidates for Percutan Cordotomy (PC) are cancer patients with unilateral localized pain if the primary malignant disease is under control. The initial success rate of 3742 cases collected by Lorenz was 75 to 96%.

Percutaneous extraluminal myelotomy: Indicated in cancer patients with pelvic or lower trunk or lower extremity pain. Kanpolat reported 15 cases, with rectal, pancreatic, colon, renal tumors without complication rate. 6 of the 15 patient had complete 5 of 15 cases had partial pain relief.

Menescephalotomy: Amano in 1998 reported 76% long-term pain relief in patients with central and deaffertation pain with an overall morbidity of 4%. No recent report of this procedure in practice.

** Key Points:**

**Learning objectives:**
This summary focuses exclusively on neurosurgical procedures against pain. SCS and periferial nerve stimulation will be discussed by other authors.

**Neurolysis:**
separation of a peripheral nerve from the surrounding structures to which is adherent. The use of internal neurolysis is clearly necessary in dissecting an injured nerve for interfacular nerve graft or to evaluate a neuroma-in-continuity.

**Trigeminal neuroectomy:**
Peripheral trigeminal neuroectomy can be useful in elderly debilitated patients who cannot undergo more substantive procedure for V1 division neuralgia. 50-60% of trigeminal neuropathic pain cases are successfully treated with neuroectomy.

**Dorsal Root ganglionection and Dorsal Rhizotomy (DR):** The largest series of DR in cancer pain was published in 1982 by Sindou and Lapras, success rate was 47% in a series of 585 patients.

**Symptpharmacology:**
Currently surgical sympathecomy is reserved for treating hyperhydrosis, sympathetically maintained pain and limited cases of vasculitis (i.e. Raynaud's syndrome). The success rate of sympathecomy in the literature after 1990 ranges from 65% to 100%.

**Dorsal Root Entry Zone lesioning:** Indications for drezotomy includes 1. Cancer pain that is limited in extent (e.g. Pancoast syndrome), 2. Persistent neuropathic pain, 3. Disabling hyperspasticity, especially when associated with pain. Surgery in the DREZ must be considered within the frame of all the methods belonging to the armamentarium of pain surgery.

**Medline myelotomy:** Gildenberg and Hirschberg (1984) performed myelotomy for visceral pain with excellent results in 8 out of 12 patients. Punctuate midline myelotomy after laminecetomy at T8 level for malignant visceral pain found efficient by Nauta et al. (2000). This technique has limited indication today.

**Anterior Cordotomy:** The ideal candidates for Percutan Cordotomy (PC) are cancer patients with unilateral localized pain if the primary malignant disease is under control. The initial success rate of 3742 cases collected by Lorenz was 75 to 96%.

**Percutaneous extraluminal myelotomy:** Indicated in cancer patients with pelvic or lower trunk or lower extremity pain. Kanpolat reported 15 cases, with rectal, pancreatic, colon, renal tumors without complication rate. 6 of the 15 patient had complete 5 of 15 cases had partial pain relief.

**Menescephalotomy:** Amano in 1998 reported 76% long-term pain relief in patients with central and deaffertation pain with an overall morbidity of 4%. No recent report of this procedure in practice.

**Medial Thalamotomy (MT):** MT is capable of alleviating neuropathic and nociceptive pain and has the advantage of low morbidity. Medial thalamotomy in any nucleus is more effective in relieving nociceptive than neuropathic pain and those results are modest: 46% relief of nociceptive usually cancer
pain and 29% in neuropathic pain.

**Stereotactic cingulotomy:** 394 patients were reported until today, in patients with benign origin 53% was useful and 47% of non-useful. In malignant pain the result was just similar. The initial good response to cingulotomy progressively fades over time.

**Hypophysectomy:** There are few clinical report on hypophysectomy for pain in the literature since 1984. Recently some center reported on few patients gamma knife hypophysectomies with limited results.

**Percutan Radiofrequency Trigeminal Gangliolysis or Rhizotomy:** In summary of several series of RF trigeminal rhizolysis 99% of patients became pain free immediately after the procedure. In a review of 1200 patients followed 1-20 years (mean 9 years), 93% reported excellent or good results, and 4% reported fair results because undesirable side effects, 1% reported poor results because of severe denervation dysesthesia. RF trigeminal rhizolysis is effective in primary trigeminal neuralgia. RF lesioning can effectively treat paroxysmal facial pain associated with tumors and multiple sclerosis.

**Percutan Retrogasserian Glycerol Rhizotomy (PRGR):** PRGR is a useful minimal invasive technique in trigeminal neuralgia when MVD is not possible. Long term pain control (7 years) was 85%; the 11 years follow up in Lundsford series showed 77% pain relief.

**Microvascular decompression (MVD) for Trigeminal Neuralgia:** Jannetta reported a total success rate of 88% at 1 year and 74% at 10 year follow up. MVD is the treatment of choice for patient with typical trigeminal neuralgia, with MRI diagnosed neurovascular compression if the patient medical condition allow the risk of craniotomy.

**Posterior Fossa Trigeminal Rhizotomy (PFTR):** Several contemporary neurosurgeons indicate PFTR when MVD surgery or other procedures failed. In 3% of patients operated with MVD no vascular compression is found. In these cases an optional treatment strategy could be partial sectioning the nerve.

**Gamma Knife Radiosurgery for Trigeminal Neuralgia:** With this method by the end of 2010 more than 17 000 patients were treated worldwide. Approximately 75% of patients achieve good (pain free on medication) or excellent results (pain free w/o medication) within 1-8 weeks of the initial treatment.

**Neuromodulative therapy includes only reversible neurostimulation type procedures:**

- **Primary Motor Cortex Stimulation (MCS):** Chronic epidural MCS can control central deafferentation pain in 45-75% of cases. The best results were observed in central post-stroke pain and trigeminal neuropathy (>90%). The results improved during the last 10 years due to better targeting of the motor cortex (fMRI, neuronavigation, SSEP, intraoperative stimulation).

- **Deep Brain Stimulation (DBS):** In general patients with refractory neuropathic pain should undergo paraesthesia producing stimulation, whereas those with nociceptive pain should undergo periventricular gray/periaqueductal gray matter stimulation, long-term success rate varies between 26% to 72%. The best results of DBS are in cancer pain, FBSS, cervical and brachial avulsions and peripheral neuropathy.

- **Gasserian Ganglion Stimulation:** Stimulation of the gasserian ganglion presents a surgical option with atypical trigeminal pain. In a large clinical series of 182 patients 92 had more than 50% pain relief and 82 were implanted. At long-term follow up 70% of patients had 75 -100% pain relief. The most benefitees were patients with neuropathic pain after intervention of the maxillary sinus, posttraumatic facial pain, and those with severe dysesthesia after trigeminal destructive procedures.

**Key References:**

2. Burchiel K.J. Surgical management of Pain ed. Thieme Verlag 2002
LIONG LIEM, MD, FIPP

BIOGRAPHICAL SKETCH
Dr. Liong Liem, MD, FIPP, is director of the multidisciplinary Pain Clinic in St. Antonius Hospital, Department of Anesthesiology, Intensive Care and Pain Medicine, Nieuwegein, The Netherlands.

FACIAL PAIN AND CERVICOGENIC HEADACHE

Objectives
Upon completion of this presentation attendees will be able to discuss:
• The pathophysiology of and risk factors for facial pain
• The diagnostic criteria for facial pain and cervicogenic headache.
• Questions to determine the differential diagnosis of facial pain.
• Physical examination to find evidence for cervicogenic headache
• Treatment options for facial pain and cervicogenic headache if conservative therapy fails.

Key Points
• Persistent idiopathic facial pain (PIFP) is described as a persistent facial pain that does not have the classical characteristics of cranial neuralgias and for which there is no obvious cause. The pathophysiology is unknown.
• Forming a diagnosis is a process of elimination of other causes of facial pain and is possible if the pain is present daily and throughout all or most of the day.
• Treatment of PIFP requires a multidisciplinary approach of psychological counseling and pharmacological therapy, Amitriptyline is the primary choice. Invasive procedures can be considered if pharmacological treatment fails.
• Cervicogenic headache is characterized by unilateral headache symptoms which arise from the neck and radiates to fronto-temporal region and possible to the supraorbital region.
• Physical examination to diagnose cervicogenic headache encompasses movement tests of the cervical facet joints and soft tissues of the neck.
• Injection of the n. occipitalis major or RF treatment can be preformed if conservative treatments falls short.

References

SANG CHUL LEE, MD, PHD, FIPP

BIOGRAPHICAL SKETCH
Prof. Sang Chul Lee is a Professor and Chairman of the Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, and the President of Korean Spinal Pain Society and Korean IASP chapter.

ULTRASOUND GUIDED TREATMENT 2011

Objectives
Upon completion of this presentation attendees will be able to discuss
• Why we should use ultrasound as a guidance method in pain treatment
• What basic principles of ultrasound imaging are
• For what ultrasound guided is used in the field of pain treatment
• Relationships between the inserted needle and inner structures
• Proper postures during ultrasound guided intervention
• How Sonoanatomy compare with real anatomy
• Examples of ultrasound application for pain treatment

Key Points
• Ultrasonography has potential usefulness in pain management including diagnosis and interventional treatment.
• The rational for performing ultrasound guided treatment is that it provides information that aids in establishing a diagnosis and prognosis, locating areas of pathology, and providing therapy via a real-time visualization.
• Ultrasonography is the only modality that allows direct visualization of relationships between the inserted needle and inner structures such as vessels or nerves in the way of target areas to avoid an iatrogenic injury of them.
• Barriers to the use of ultrasound in clinical practice include necessity of training for operation due to some limitations of ultrasound-guided intervention such as unrecognized intravascular injection.
• Expected outcomes include ruling in or out area or areas of pathology, facilitating treatment, better forecasting of prognosis and future treatment options.

References
HIGH FREQUENCY SPINAL CORD STIMULATION IN THE MANAGEMENT OF AXIAL BACK PAIN

Objectives
Upon completion of this presentation attendees will be able to discuss

• The role of conventional Spinal Cord Stimulation (SCS) in management of Failed back Surgery Syndrome (FBSS).
• Limitations of conventional SCS in the management of Axial Back Pain (ABP)
• Strategies used to improve the efficacy of the conventional SCS
• What is high frequency stimulation?
• How does high frequency stimulation work? How safe is it?
• What are the advantages of high frequency stimulation for patients, operators and providers?
• Future direction of high frequency SCS

Key Points
• Spinal Cord Stimulation is evidence-based treatment used in the management of chronic pain conditions.
• While SCS is very effective for radicular pain, one notable area that SCS has had less success in is ABP, which is a mix of nociceptive and neuropathic pain.
• In conventional SCS, paraesthesia coverage has been essential for pain relief. However, coverage of low back pain without dorsal root stimulation and without undesirable stimulation is difficult to accomplish.
• One promising approach for this unmet need is high frequency SCS using up to 10 KHZ.
• In a multi-centre prospective European open label study with 84 implanted patients, high frequency SCS technology showed significant relief for chronic back pain in difficult-to-treat patients, such as predominant back pain patients.
• Leads can be placed in anatomic midline rather than physiologic midline, making the procedure simpler. Paraesthesia mapping step is not required, making the time for high frequency SCS surgery more predictable and potentially shorter.
• Future directions of HF SCS includes use of different algorithms in programming, different applications and advances in equipment technology.

References
MURRAY H. ROSENTHAL, DO, FAPA

BIOGRAPHICAL SKETCH
Dr. Murray Rosenthal, a board-certified psychiatrist and Fellow of the American Psychiatric Association, is Chief Medical Officer of Millennium Laboratories. Prior to joining Millennium, Dr. Rosenthal was Senior Medical Director and CEO of California Clinical Trials (CCT), a multi-site, phase 1-4 CNS research group. During his tenure at CCT he conducted over 450 clinical trials in all areas of Central Nervous System (CNS) research.

THE ROLE OF URINE DRUG TESTING IN PAIN MANAGEMENT

Objectives
Upon completion of this presentation attendees will be able to discuss
• The rationale for performing urine drug testing (UDT) on patients taking opioids
• How do Point of Care Urine Testing (POCT) and laboratory confirmation compare
• Limitations of POCT
• What are common objections to UDT testing?
• APS Guidelines for testing; when to test
• How to assess false positives and negatives
• Using UDT to assess you patient and practice; what could unexpected results indicate
• Current and future research

Key Points
• Physicians guessing at patient compliance on opioids is less than chance
• UDT is becoming a part of physician-patient treatment contract
• Patients need to understand the UDT as a routine procedure like monitoring Bp in hypertension.
• The POCT and confirmation have different uses based upon their sensitivity. One gives instant snapshot and the other can be used over time to assess levels compare to large patient populations on similar medications.
• Testing should be both routine and at key times during changes in treatment or significant changes in a patient’s clinical picture.
• By assessing huge databases of patient samples, we have observed patterns of use and misuse which will be discussed

References